| Horng H Chen, MD | |
|
200 1st St Sw, Rochester, MN 55905-0001 | |
| (507) 284-2511 | |
| Not Available |
| Full Name | Horng H Chen |
|---|---|
| Gender | Male |
| Speciality | Advanced Heart Failure And Transplant Cardiology |
| Experience | 31 Years |
| Location | 200 1st St Sw, Rochester, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073599320 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mayo Clinic Hospital Rochester | Rochester, MN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Winneshiek Medical Center | 4688582935 | 74 |
| Mayo Clinic | 6507778255 | 4232 |
News Archive
CyDex Pharmaceuticals Inc., a specialty pharmaceutical company, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a patent to CyDex entitled "Sulfoalkyl Ether Cyclodextrin Compositions." This patent, along with other previously issued technology patents, will provide broad protection for CyDex's Captisol® technology until 2029.
On behalf of citizens of our states, we write to let you know that that we oppose the actions of the state Attorneys General who have filed a lawsuit to challenge the constitutionality of the Patient Protection and Affordable Care Act. We believe their legal efforts will fail in court, unnecessarily delay the urgent need to get our citizens access to health care and waste our state tax dollars.
A new study led by University of Iowa researchers has found an unexpected new link between this inflammation in heart muscle following a heart attack and a previously known enzyme called calcium/calmodulin-dependent protein kinase II or CaM kinase II.
A new imaging test may provide the ability to identify ovarian cancer patients who are candidates for an emerging treatment that targets a key enzyme cancer cells need to survive.
› Verified 4 days ago
| Entity Name | Mayo Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922074434 PECOS PAC ID: 6507778255 Enrollment ID: O20031103000285 |
News Archive
CyDex Pharmaceuticals Inc., a specialty pharmaceutical company, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a patent to CyDex entitled "Sulfoalkyl Ether Cyclodextrin Compositions." This patent, along with other previously issued technology patents, will provide broad protection for CyDex's Captisol® technology until 2029.
On behalf of citizens of our states, we write to let you know that that we oppose the actions of the state Attorneys General who have filed a lawsuit to challenge the constitutionality of the Patient Protection and Affordable Care Act. We believe their legal efforts will fail in court, unnecessarily delay the urgent need to get our citizens access to health care and waste our state tax dollars.
A new study led by University of Iowa researchers has found an unexpected new link between this inflammation in heart muscle following a heart attack and a previously known enzyme called calcium/calmodulin-dependent protein kinase II or CaM kinase II.
A new imaging test may provide the ability to identify ovarian cancer patients who are candidates for an emerging treatment that targets a key enzyme cancer cells need to survive.
› Verified 4 days ago
| Entity Name | Mayo Clinic Health System-lake City |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164463659 PECOS PAC ID: 1951213487 Enrollment ID: O20031104000095 |
News Archive
CyDex Pharmaceuticals Inc., a specialty pharmaceutical company, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a patent to CyDex entitled "Sulfoalkyl Ether Cyclodextrin Compositions." This patent, along with other previously issued technology patents, will provide broad protection for CyDex's Captisol® technology until 2029.
On behalf of citizens of our states, we write to let you know that that we oppose the actions of the state Attorneys General who have filed a lawsuit to challenge the constitutionality of the Patient Protection and Affordable Care Act. We believe their legal efforts will fail in court, unnecessarily delay the urgent need to get our citizens access to health care and waste our state tax dollars.
A new study led by University of Iowa researchers has found an unexpected new link between this inflammation in heart muscle following a heart attack and a previously known enzyme called calcium/calmodulin-dependent protein kinase II or CaM kinase II.
A new imaging test may provide the ability to identify ovarian cancer patients who are candidates for an emerging treatment that targets a key enzyme cancer cells need to survive.
› Verified 4 days ago
| Entity Name | Mayo Clinic Health System-southeast Minnesota Region |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891701637 PECOS PAC ID: 4385556703 Enrollment ID: O20031104000408 |
News Archive
CyDex Pharmaceuticals Inc., a specialty pharmaceutical company, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a patent to CyDex entitled "Sulfoalkyl Ether Cyclodextrin Compositions." This patent, along with other previously issued technology patents, will provide broad protection for CyDex's Captisol® technology until 2029.
On behalf of citizens of our states, we write to let you know that that we oppose the actions of the state Attorneys General who have filed a lawsuit to challenge the constitutionality of the Patient Protection and Affordable Care Act. We believe their legal efforts will fail in court, unnecessarily delay the urgent need to get our citizens access to health care and waste our state tax dollars.
A new study led by University of Iowa researchers has found an unexpected new link between this inflammation in heart muscle following a heart attack and a previously known enzyme called calcium/calmodulin-dependent protein kinase II or CaM kinase II.
A new imaging test may provide the ability to identify ovarian cancer patients who are candidates for an emerging treatment that targets a key enzyme cancer cells need to survive.
› Verified 4 days ago
| Entity Name | Mayo Clinic Health System-southwest Minnesota Region |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578545422 PECOS PAC ID: 4688585771 Enrollment ID: O20031110000134 |
News Archive
CyDex Pharmaceuticals Inc., a specialty pharmaceutical company, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a patent to CyDex entitled "Sulfoalkyl Ether Cyclodextrin Compositions." This patent, along with other previously issued technology patents, will provide broad protection for CyDex's Captisol® technology until 2029.
On behalf of citizens of our states, we write to let you know that that we oppose the actions of the state Attorneys General who have filed a lawsuit to challenge the constitutionality of the Patient Protection and Affordable Care Act. We believe their legal efforts will fail in court, unnecessarily delay the urgent need to get our citizens access to health care and waste our state tax dollars.
A new study led by University of Iowa researchers has found an unexpected new link between this inflammation in heart muscle following a heart attack and a previously known enzyme called calcium/calmodulin-dependent protein kinase II or CaM kinase II.
A new imaging test may provide the ability to identify ovarian cancer patients who are candidates for an emerging treatment that targets a key enzyme cancer cells need to survive.
› Verified 4 days ago
| Entity Name | Mayo Clinic Health System-franciscan Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629056049 PECOS PAC ID: 0345152443 Enrollment ID: O20040708000447 |
News Archive
CyDex Pharmaceuticals Inc., a specialty pharmaceutical company, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a patent to CyDex entitled "Sulfoalkyl Ether Cyclodextrin Compositions." This patent, along with other previously issued technology patents, will provide broad protection for CyDex's Captisol® technology until 2029.
On behalf of citizens of our states, we write to let you know that that we oppose the actions of the state Attorneys General who have filed a lawsuit to challenge the constitutionality of the Patient Protection and Affordable Care Act. We believe their legal efforts will fail in court, unnecessarily delay the urgent need to get our citizens access to health care and waste our state tax dollars.
A new study led by University of Iowa researchers has found an unexpected new link between this inflammation in heart muscle following a heart attack and a previously known enzyme called calcium/calmodulin-dependent protein kinase II or CaM kinase II.
A new imaging test may provide the ability to identify ovarian cancer patients who are candidates for an emerging treatment that targets a key enzyme cancer cells need to survive.
› Verified 4 days ago
| Entity Name | Mayo Clinic Health System-fairmont |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366410862 PECOS PAC ID: 4981694981 Enrollment ID: O20040719000142 |
News Archive
CyDex Pharmaceuticals Inc., a specialty pharmaceutical company, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a patent to CyDex entitled "Sulfoalkyl Ether Cyclodextrin Compositions." This patent, along with other previously issued technology patents, will provide broad protection for CyDex's Captisol® technology until 2029.
On behalf of citizens of our states, we write to let you know that that we oppose the actions of the state Attorneys General who have filed a lawsuit to challenge the constitutionality of the Patient Protection and Affordable Care Act. We believe their legal efforts will fail in court, unnecessarily delay the urgent need to get our citizens access to health care and waste our state tax dollars.
A new study led by University of Iowa researchers has found an unexpected new link between this inflammation in heart muscle following a heart attack and a previously known enzyme called calcium/calmodulin-dependent protein kinase II or CaM kinase II.
A new imaging test may provide the ability to identify ovarian cancer patients who are candidates for an emerging treatment that targets a key enzyme cancer cells need to survive.
› Verified 4 days ago
| Entity Name | Winneshiek Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093857393 PECOS PAC ID: 4688582935 Enrollment ID: O20050502000593 |
News Archive
CyDex Pharmaceuticals Inc., a specialty pharmaceutical company, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a patent to CyDex entitled "Sulfoalkyl Ether Cyclodextrin Compositions." This patent, along with other previously issued technology patents, will provide broad protection for CyDex's Captisol® technology until 2029.
On behalf of citizens of our states, we write to let you know that that we oppose the actions of the state Attorneys General who have filed a lawsuit to challenge the constitutionality of the Patient Protection and Affordable Care Act. We believe their legal efforts will fail in court, unnecessarily delay the urgent need to get our citizens access to health care and waste our state tax dollars.
A new study led by University of Iowa researchers has found an unexpected new link between this inflammation in heart muscle following a heart attack and a previously known enzyme called calcium/calmodulin-dependent protein kinase II or CaM kinase II.
A new imaging test may provide the ability to identify ovarian cancer patients who are candidates for an emerging treatment that targets a key enzyme cancer cells need to survive.
› Verified 4 days ago
| Entity Name | Mayo Clinic Health System St James |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023177730 PECOS PAC ID: 9537170352 Enrollment ID: O20060509000021 |
News Archive
CyDex Pharmaceuticals Inc., a specialty pharmaceutical company, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a patent to CyDex entitled "Sulfoalkyl Ether Cyclodextrin Compositions." This patent, along with other previously issued technology patents, will provide broad protection for CyDex's Captisol® technology until 2029.
On behalf of citizens of our states, we write to let you know that that we oppose the actions of the state Attorneys General who have filed a lawsuit to challenge the constitutionality of the Patient Protection and Affordable Care Act. We believe their legal efforts will fail in court, unnecessarily delay the urgent need to get our citizens access to health care and waste our state tax dollars.
A new study led by University of Iowa researchers has found an unexpected new link between this inflammation in heart muscle following a heart attack and a previously known enzyme called calcium/calmodulin-dependent protein kinase II or CaM kinase II.
A new imaging test may provide the ability to identify ovarian cancer patients who are candidates for an emerging treatment that targets a key enzyme cancer cells need to survive.
› Verified 4 days ago
| Entity Name | Mayo Clinic Health System-lake City |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1538113022 PECOS PAC ID: 1951213487 Enrollment ID: O20070711000490 |
News Archive
CyDex Pharmaceuticals Inc., a specialty pharmaceutical company, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a patent to CyDex entitled "Sulfoalkyl Ether Cyclodextrin Compositions." This patent, along with other previously issued technology patents, will provide broad protection for CyDex's Captisol® technology until 2029.
On behalf of citizens of our states, we write to let you know that that we oppose the actions of the state Attorneys General who have filed a lawsuit to challenge the constitutionality of the Patient Protection and Affordable Care Act. We believe their legal efforts will fail in court, unnecessarily delay the urgent need to get our citizens access to health care and waste our state tax dollars.
A new study led by University of Iowa researchers has found an unexpected new link between this inflammation in heart muscle following a heart attack and a previously known enzyme called calcium/calmodulin-dependent protein kinase II or CaM kinase II.
A new imaging test may provide the ability to identify ovarian cancer patients who are candidates for an emerging treatment that targets a key enzyme cancer cells need to survive.
› Verified 4 days ago
| Entity Name | Mayo Clinic Health System St James |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1639198732 PECOS PAC ID: 9537170352 Enrollment ID: O20080108000344 |
News Archive
CyDex Pharmaceuticals Inc., a specialty pharmaceutical company, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a patent to CyDex entitled "Sulfoalkyl Ether Cyclodextrin Compositions." This patent, along with other previously issued technology patents, will provide broad protection for CyDex's Captisol® technology until 2029.
On behalf of citizens of our states, we write to let you know that that we oppose the actions of the state Attorneys General who have filed a lawsuit to challenge the constitutionality of the Patient Protection and Affordable Care Act. We believe their legal efforts will fail in court, unnecessarily delay the urgent need to get our citizens access to health care and waste our state tax dollars.
A new study led by University of Iowa researchers has found an unexpected new link between this inflammation in heart muscle following a heart attack and a previously known enzyme called calcium/calmodulin-dependent protein kinase II or CaM kinase II.
A new imaging test may provide the ability to identify ovarian cancer patients who are candidates for an emerging treatment that targets a key enzyme cancer cells need to survive.
› Verified 4 days ago
| Entity Name | Mayo Clinic Health System-northwest Wisconsin Region Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235588831 PECOS PAC ID: 4385553627 Enrollment ID: O20170522002864 |
News Archive
CyDex Pharmaceuticals Inc., a specialty pharmaceutical company, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a patent to CyDex entitled "Sulfoalkyl Ether Cyclodextrin Compositions." This patent, along with other previously issued technology patents, will provide broad protection for CyDex's Captisol® technology until 2029.
On behalf of citizens of our states, we write to let you know that that we oppose the actions of the state Attorneys General who have filed a lawsuit to challenge the constitutionality of the Patient Protection and Affordable Care Act. We believe their legal efforts will fail in court, unnecessarily delay the urgent need to get our citizens access to health care and waste our state tax dollars.
A new study led by University of Iowa researchers has found an unexpected new link between this inflammation in heart muscle following a heart attack and a previously known enzyme called calcium/calmodulin-dependent protein kinase II or CaM kinase II.
A new imaging test may provide the ability to identify ovarian cancer patients who are candidates for an emerging treatment that targets a key enzyme cancer cells need to survive.
› Verified 4 days ago
| Entity Name | Mayo Clinic Health System-southwest Minnesota Region |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1740256668 PECOS PAC ID: 4688585771 Enrollment ID: O20171011003933 |
News Archive
CyDex Pharmaceuticals Inc., a specialty pharmaceutical company, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a patent to CyDex entitled "Sulfoalkyl Ether Cyclodextrin Compositions." This patent, along with other previously issued technology patents, will provide broad protection for CyDex's Captisol® technology until 2029.
On behalf of citizens of our states, we write to let you know that that we oppose the actions of the state Attorneys General who have filed a lawsuit to challenge the constitutionality of the Patient Protection and Affordable Care Act. We believe their legal efforts will fail in court, unnecessarily delay the urgent need to get our citizens access to health care and waste our state tax dollars.
A new study led by University of Iowa researchers has found an unexpected new link between this inflammation in heart muscle following a heart attack and a previously known enzyme called calcium/calmodulin-dependent protein kinase II or CaM kinase II.
A new imaging test may provide the ability to identify ovarian cancer patients who are candidates for an emerging treatment that targets a key enzyme cancer cells need to survive.
› Verified 4 days ago
| Entity Name | Mayo Clinic Health System-southwest Minnesota Region |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1124035282 PECOS PAC ID: 4688585771 Enrollment ID: O20171011003939 |
News Archive
CyDex Pharmaceuticals Inc., a specialty pharmaceutical company, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a patent to CyDex entitled "Sulfoalkyl Ether Cyclodextrin Compositions." This patent, along with other previously issued technology patents, will provide broad protection for CyDex's Captisol® technology until 2029.
On behalf of citizens of our states, we write to let you know that that we oppose the actions of the state Attorneys General who have filed a lawsuit to challenge the constitutionality of the Patient Protection and Affordable Care Act. We believe their legal efforts will fail in court, unnecessarily delay the urgent need to get our citizens access to health care and waste our state tax dollars.
A new study led by University of Iowa researchers has found an unexpected new link between this inflammation in heart muscle following a heart attack and a previously known enzyme called calcium/calmodulin-dependent protein kinase II or CaM kinase II.
A new imaging test may provide the ability to identify ovarian cancer patients who are candidates for an emerging treatment that targets a key enzyme cancer cells need to survive.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Horng H Chen, MD 200 1st St Sw, Rochester, MN 55905-0001 Ph: (507) 284-2511 | Horng H Chen, MD 200 1st St Sw, Rochester, MN 55905-0001 Ph: (507) 284-2511 |
News Archive
CyDex Pharmaceuticals Inc., a specialty pharmaceutical company, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a patent to CyDex entitled "Sulfoalkyl Ether Cyclodextrin Compositions." This patent, along with other previously issued technology patents, will provide broad protection for CyDex's Captisol® technology until 2029.
On behalf of citizens of our states, we write to let you know that that we oppose the actions of the state Attorneys General who have filed a lawsuit to challenge the constitutionality of the Patient Protection and Affordable Care Act. We believe their legal efforts will fail in court, unnecessarily delay the urgent need to get our citizens access to health care and waste our state tax dollars.
A new study led by University of Iowa researchers has found an unexpected new link between this inflammation in heart muscle following a heart attack and a previously known enzyme called calcium/calmodulin-dependent protein kinase II or CaM kinase II.
A new imaging test may provide the ability to identify ovarian cancer patients who are candidates for an emerging treatment that targets a key enzyme cancer cells need to survive.
› Verified 4 days ago
Emily Leasure, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Jorge A Velosa, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Michael Ruediger Mueller, Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Mr. Karun Singh Badwal, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Michal Reid, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Katherine Desprez Wick, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Dr. Allison Bock, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 |